<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00639522</url>
  </required_header>
  <id_info>
    <org_study_id>LPS-GC-01-2008</org_study_id>
    <nct_id>NCT00639522</nct_id>
  </id_info>
  <brief_title>Dose Escalation Study of Liposomal Paclitaxel With/Without Capecitabine in Patients With Advanced Gastric Carcinoma</brief_title>
  <official_title>A Phase I Clinical Trial to Investigate the Maximum Tolerated Dose and Pharmacokinetics of Liposomal Paclitaxel With/Without Capecitabine in Chinese Cancer Patients With Advanced Gastric Carcinoma.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nanjing Sike Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nanjing Sike Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the maximum tolerated dose and pharmacokinetics
      of liposomal paclitaxel with/without capecitabine in Chinese cancer patients with advanced
      gastric carcinoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The maximum tolerated dose (MTD) and pharmacokinetics of a new formulation of taxane
      (liposomal paclitaxel) have never been studied in Chinese cancer patients, either alone or
      with capecitabine .This clinical trial is designed to find out the MTD and pharmacokinetics
      of liposomal paclitaxel with a beginning dose of 175mg/m2 with/without Capecitabine in
      Chinese patients with advanced gastric carcinoma.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>May 2008</start_date>
  <completion_date type="Anticipated">December 2009</completion_date>
  <primary_completion_date type="Anticipated">September 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose limiting toxicity</measure>
    <time_frame>6 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics</measure>
    <time_frame>48 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">18</enrollment>
  <condition>Gastric Carcinoma</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Liposomal paclitaxel and capecitabine</intervention_name>
    <description>Patients will be given Liposomal paclitaxel intravenously in 3 hours with the dose of 175mg/m2、185mg/m2、195mg/m2、 200mg/m2、205mg/m2 and so on ,at the first day of chemotherapy. Capecitabine will be given on d1 to d14 with the dose of 185mg/m2、200mg/m2 or d8 to d21 with the dose of 175mg/m2、195mg/m2、205mg/m2 .Cycle duration will be 21 days. Each patient will receive 2 cycles of therapy. Only in the first cycle blood samples will be taken on 16 points in 48 hours after the infusion of liposomal paclitaxel.</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically verified gastric carcinoma of advanced stages which is unsuitable for
             surgery;

          -  No prior systemic chemotherapy with taxane at least 6 months before the recruitment;

          -  At least one measurable tumor according to RECIST standard, with at least one diameter
             ≥20mm assessed by traditional imaging technique or MRI, or with a diameter twice of
             the thickness of scan layer (or ≥10-16mm) under spiral CT; Eastern Cooperative
             Oncology Group (ECOG) performance status (PS) 0-1;

          -  Patients who are expected to live at least 3 months;

          -  Obtaining informed consent;

        Exclusion Criteria:

          -  Receiving other chemotherapy or radiotherapy during the administration;

          -  Symptomatic metastatic brain tumor;

          -  Allergy to any study medication;

          -  Pregnancy or breast feeding;

          -  Severe heart diseases;

          -  Uncontrolled mental diseases;

          -  Abnormal liver and renal functions, which are measured by AST/ALT and BUN/Cr;

          -  Neutrophils（ANC）&lt;2000/μL;platelets&lt;100，000/μL;hemoglobin（HB）&lt;9.0 g/dL;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jinwan Wang, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cancer Hospital, Chinese Academy of Medical Science</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jinwan Wang, Doctor</last_name>
    <phone>086-010-87788842</phone>
    <email>hsunyk@tom.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Chi Yihebali, Doctor</last_name>
    <phone>086-010-87788118</phone>
    <email>yihebalichi@yahoo.com.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cancer Hospital,Chinese Academy of Medical Science</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100021</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jinwan Wang, Doctor</last_name>
      <phone>086-010-87788842</phone>
      <email>hsunyk@tom.com</email>
    </contact>
    <contact_backup>
      <last_name>Chi Yihebali, Doctor</last_name>
      <phone>086-010-87788118</phone>
      <email>yihebalichi@yahoo.com.cn</email>
    </contact_backup>
    <investigator>
      <last_name>Jinwan Wang, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 14, 2008</study_first_submitted>
  <study_first_submitted_qc>March 19, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 20, 2008</study_first_posted>
  <last_update_submitted>April 14, 2009</last_update_submitted>
  <last_update_submitted_qc>April 14, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 15, 2009</last_update_posted>
  <responsible_party>
    <name_title>Prof. Jinwan Wang</name_title>
    <organization>Cancer Institute and Hospital,Chinese Academy of Medical Science</organization>
  </responsible_party>
  <keyword>Liposomal paclitaxel</keyword>
  <keyword>Maximum tolerated dose</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Gastric carcinoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

